A Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602).
Phase of Trial: Phase II
Latest Information Update: 06 Apr 2018
At a glance
- Drugs Ipilimumab/nivolumab (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms UNISoN
- 22 Oct 2017 Status changed from not yet recruiting to recruiting.
- 12 Sep 2017 Planned initiation date changed from 1 Sep 2017 to 1 Oct 2017.
- 07 Jun 2017 New trial record